miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2

Oncology Letters

Volumn 6, Issue 2, 2013, Pages 359-366

  Nian, Weiqi ^a,b   Ao, Xujun ^b,c   Wu, Yongzhong ^a   Huang, Yi ^d   Shao, Jianghe ^a   Wang, Yiming ^a   Chen, Zhengtang ^b   Chen, Fanglin ^b   Wang, Donglin ^a  

^a Chongqing Tumor Hospital   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c 532 Hospital of People's Liberation Army   (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Metastasis; miR 223; Non small cell lung cancer; Self renewal; Tumor suppressor

Indexed keywords

CYCLIN DEPENDENT KINASE 2; GELATINASE B; MICRORNA 223; SOMATOMEDIN C RECEPTOR; STEM CELL ANTIGEN 1; TUMOR SUPPRESSOR PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; G2 PHASE CELL CYCLE CHECKPOINT; IMMUNOFLUORESCENCE TEST; LEWIS CARCINOMA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SPECTROPHOTOMETRY; TUMOR VOLUME; WESTERN BLOTTING; WOUND HEALING;

EID: 84879486215     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1375     Document Type: Article

References (39)

1. Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907, 2010.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism and function. Cell 116: 281-297, 2004.
4. Bueno MJ, Pérez de Castro I and Malumbres M: Control of cell proliferation pathways by microRNAs. Cell Cycle 7: 3143-3148, 2008.
5. Lee CT, Risom T and Strauss WM: MicroRNAs in mammalian development. Birth Defects Res C Embryo Today 78: 129-139, 2006.
6. Jovanovic M and Hengartner MO: miRNAs and apoptosis: RNAs to die for. Oncogene 25: 6176-6187, 2006.
7. Mendell JT: miRiad roles for the miR-17-92 cluster in development and disease. Cell 133: 217-222, 2008.
8. Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
9. Kent OA and Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 25: 6188-6196, 2006.
10. Kumar MS, Erkeland SJ and Pester RE: Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 105: 3903-3908, 2008.
11. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C and Bozzoni I: Aminicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 123: 819-831, 2005.
12. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, LamMH and Kirak O: Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451: 1125-1129, 2008.
13. Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao QL, Wu W and Wu XZ: MiR-223 suppresses cell proliferation by targeting IGF-1R. Plos One 6: e27008, 2011.
14. Liu Q, Zhang M, Jiang X, Zhang Z, Dai L, Min S, Wu X, HeQ, Liu J, Zhang Y, Zhang Z and Yang R: miR-223 suppresses differentiation of tumor-induced CD11b+ Gr1+ myeloid-derived suppressor cells from bone marrow cells. Int J Cancer 129: 2662-2673, 2011.
15. Kang W, Tong JH, Chan AW, Lung RW, Chau SL, Wong QW, Wong N, Yu J, Cheng AS and To KF: Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One 7: e33919, 2012.
16. Li S, Li Z, Guo F, Qin X, Liu B, Lei Z, Song Z, Sun L, Zhang HT, You J and Zhou Q: miR-223 regulates migration and invasion by targeting Artemin in human esophageal carcinoma. J Biomed Sci 18: 24, 2011.
17. Wu L, Li H, Jia CY, Cheng W, Yu M, Peng M, Zhu Y, ZhaoQ, Dong YW, Shao K, Wu A and Wu XZ: MicroRNA-223 regulates FOXO1 expression and cell proliferation. FEBS Lett 586: 1038-1043, 2012.
18. Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM and DeFloraS: Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J 23: 806-812, 2009.
19. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED and Harris CC: Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 130: 1378-1386, 2012.
20. Nian WQ, Chen FL, Ao XJ and Chen ZT: CXCR4 positive cells from Lewis lung carcinoma cell line have cancer metastatic stem cell characteristics. Mol Cell Biochem 355: 241-248, 2011.
21. Nian WQ, Chen FL, Ao XJ and Chen ZT: Lowly expression of miR-223 in CXCR4 positive cells from Lewis lung carcinoma cell line and its target gene prediction. Di San Jun Yi Da Xue Xue Bao 31: 2202-2205, 2009 (In Chinese).
22. Moon DO, Kim MO, Kang SH, Lee KJ, Heo MS, Choi KS, ChoiYH and Kim GY: Induction of G2/M arrest, endoreduplication and apoptosis by actin depolymerization agent pextenotoxin-2 in human leukemia cells, involving activation of ERK and JNK. Biochem Pharmacol 76: 312-321, 2008.
23. Dufourny B, Alblas J and van Teeffelen HA: Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 272: 31163-31171, 1997.
24. Khandwala HM, McCutcheon IE and Flyvbjerg A: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21: 215-244, 2000.
25. Blakesley VA, Stannard BS and Kalebic T: Role of the IGF-I receptor in mutagenesis and tumor promotion. J Endocrinol 152: 339-344, 1997.
26. Moats-Staats BM, Price WA, Xu L, Jarvis HW and StilesAD: Regulation of the insulin-like growth factor system during normal rat lung development. Am J Respir Cell Mol Biol 12: 56-64, 1995.
27. Linnerth NM, Siwicky MD, Campbell CI, Watson KL, PetrikJJ, Whitsett JA and Moorehead RA: Type I insulin-like growth factor receptor induces pulmonary tumorigenesis. Neoplasia 11: 672-682, 2009.
28. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, HaeuwJF and Corvaia N: A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113: 316-328, 2005.
29. Cosaceanu D, Carapancea M, Castro J, Ekedahl J, Kanter L, Lewensohn R and Dricu A: Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett 222: 173-181, 2005.
30. Chung JH and Bunz F: Cdk2 Is required for p53-independent G2/M checkpoint control. PLoS Genet 6: e1000863, 2010.
31. Goldstone S, Pavey S, Forrest A, Sinnamon J and Gabrielli B: Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR. Oncogene 209: 921-932, 2001.
32. Strömberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, Lennartsson J, Hellman U, Carlson K, OsterborgA, Vanderkerken K, Nilsson K and Jernberg-Wiklund H: IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107: 669-678, 2006.
33. Lin CC, Kuo CT, Cheng CY, Wu CY, Lee CW, Hsieh HL, Lee IT and Yang CM: IL-1β promotes A549 cell migration via MAPKs/AP-1-and NF-κB-dependent matrix metalloproteinase-9 expression. Cell Signal 21: 1652-1662, 2009.
34. Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, Stack MS and Hudson LG: Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 61: 1855-1861, 2001.
35. Wu X, Pang L, Lei W, Lu W, Li J, Li Z, Frassica FJ, Chen X, Wan M and Cao X: Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 7: 571-580, 2010.
36. Lu G, Haider HK, Jiang S and Ashraf M: Sca-1+ stem cell survival and engraftment in the infarcted heart: dual role for preconditioning induced connexin-43. Circulation 119: 2587-2596, 2009.
37. Jin C, Samuelson L, Cui CB, Sun Y and Gerber DA: MAPK/ERK and Wnt/β-catenin pathways are synergistically involved in proliferation of Sca-1 positive hepatic progenitor cells. Biochem Biophys Res Commun 409: 803-807, 2011.
38. Valentinis B, Morrione A, Peruzzi F, Prisco M and Reiss K: Antiapoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion. Oncogene 18: 1827-1836, 1999.
39. Wang YK, Zhu YL, Qiu FM, Zhang T, Chen ZG, Zheng S and HuangJ: Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 31: 1376-1380, 2010.